{
    "guideline_id": "2024CSCO抗肿瘤药物相关肝损伤诊疗指南- .txt",
    "cancer_info": {
        "cancer_name": "All Malignancies"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Diagnosis of Antitumor Drug-Related Liver Injury (DILI)",
            "recommendation_type": "Diagnostic Criteria",
            "recommendation_content": "Thresholds: ALT ≥5×ULN for hepatocellular injury type; ALP ≥2×ULN with elevated GGT for cholestatic type; ALT ≥3×ULN + TBil ≥2×ULN for mixed type or high risk of severe injury. Use RUCAM scale for causality assessment (score ≥8: highly probable; 6-8: probable). Exclude other causes including viral hepatitis, autoimmune hepatitis, biliary obstruction, tumor metastasis, and ischemic liver disease. Liver biopsy indicated if unable to exclude autoimmune hepatitis, unresponsive to steroids for immune checkpoint inhibitors (ICIs) toxicity, or persistent enzyme elevation >180 days.",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "General Management of DILI",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Immediately discontinue suspected drugs per FDA criteria (ALT/AST >8×ULN or ALT/AST >3×ULN + TBil >2×ULN). For hepatocellular/mixed type: first-line magnesium isoglycyrrhizinate or bicyclol; second-line glycyrrhizin diammonium, polyene phosphatidylcholine, or silymarin. For cholestatic type: first-line ursodeoxycholic acid; second-line S-adenosylmethionine or tauroursodeoxycholic acid.",
            "treatment_line": "First-line and Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation for first-line; Level II Recommendation for second-line",
            "evidence_level": "Evidence IA for first-line; Evidence 2B for second-line"
        },
        {
            "clinical_context": "Management of Immune Checkpoint Inhibitors (ICIs) Liver Toxicity",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Grade 1-2: pause ICIs and monitor liver enzymes; if persistent elevation, administer oral prednisone 0.5-1 mg/kg/day. Grade 3-4: permanently discontinue ICIs and administer intravenous methylprednisolone 1-2 mg/kg/day; add mycophenolate mofetil or tacrolimus if ineffective. Taper steroids over 4-6 weeks after enzyme normalization (reduce by 10 mg every 3 days to 10 mg/day maintenance).",
            "treatment_line": "Based on severity grade",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Restarting Antitumor Therapy After DILI",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "For periodic dosing: restart original regimen when liver enzymes recover to ≤ Grade 1 with close monitoring. For continuous dosing: reduce dose for Grade 1-2 liver injury; switch to low-hepatotoxicity regimen for Grade 3-4 injury.",
            "treatment_line": "Based on dosing type and severity",
            "biomarker_requirements": [],
            "recommendation_level": "",
            "evidence_level": ""
        },
        {
            "clinical_context": "Screening for HBV Reactivation",
            "recommendation_type": "Preventive Measure",
            "recommendation_content": "Test all patients for HBsAg and anti-HBc before antitumor treatment. For HBsAg-positive or anti-HBc-positive patients, test HBV DNA. For medium-high risk drugs (e.g., anti-CD20 monoclonal antibodies, high-dose steroids), administer prophylactic antivirals (entecavir or tenofovir).",
            "treatment_line": "",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HBsAg",
                    "status": "Tested",
                    "testing_guidance": "Test all patients before treatment"
                },
                {
                    "biomarker_name": "Anti-HBc",
                    "status": "Tested",
                    "testing_guidance": "Test all patients before treatment"
                },
                {
                    "biomarker_name": "HBV DNA",
                    "status": "Test if HBsAg or anti-HBc positive",
                    "testing_guidance": "Test if initial markers are positive"
                }
            ],
            "recommendation_level": "",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Key indicators (ALT, AST, ALP, GGT, TBil, INR) assess liver function and injury severity. HBV screening predicts and prevents reactivation during antitumor therapy, especially in high-risk patients."
    },
    "tcm_recommendations": [
        {
            "syndrome_type": "Hepatocellular Injury or Mixed Type",
            "tcm_treatment_plan": "Hugan Pian or Wuling Jiaonang as adjunctive therapy",
            "recommendation_grade": "Level II Recommendation"
        },
        {
            "syndrome_type": "Cholestatic Type",
            "tcm_treatment_plan": "Yinzhi Huang preparations as adjunctive therapy",
            "recommendation_grade": "Level II Recommendation"
        }
    ]
}